Preliminary research suggest that Retatrutide – a dual agonist of incretin and glucose-dependent insulinotropic polypeptide receptors – offers a substantial advance in metabolic management therapies. Unlike existing medications , the peptide appears to affect appetite and metabolic utilization by means of separate mechanisms . Despite more inve